Note the description below of who should read The Patient, according to Wolters Kluwer Health.
I find this rather interesting since I AM THE PATIENT and oftentimes the Healthcare Payor. But it appears that this material is geared towards everybody BUT the patient.
Admittedly, I am emotionally torn when it comes to socioeconomic and pharmacoeconomic discussions. If I weren't painfully aware that pharma companies often price and position their drugs based on life-saving and quality-of-life implications, I would be cheering pharmacoeconomic research which can lead to the availability of MS drugs in Britain through NHS.
The benchmark journal for peer-reviewed authoritative and practical articles on the application of pharmacoeconomics and quality-of-life assessment to optimum drug therapy and health outcomes.
An invaluable source of applied pharmacoeconomic original research and educational material for the healthcare decision maker. The journal is dedicated to the clear communication of complex pharmacoeconomic issues related to patient care and drug utilization.
Every issue takes into account the needs of key groups in this discipline, making it essential reading for:
- Formulary managers
- Healthcare providers and institutions
- Healthcare policy & decision makers
- Executives in managed care and health maintenance organizations
- Employers and other healthcare payors
- Executives in pharmaceutical companies and
- Pharmacoeconomic academics